Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical
haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult
patients but several studies have shown a high interindividual kinetics variability. A
tailored administration of eculizumab based on therapeutic drug monitoring will be compared
with real-life administration in adults suffering from an atypical haemolytic uraemic
syndrome. The objective is to improve efficiency of eculizumab administration.